Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats. (Q54263630)

27 May 2018

title

Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats. (English)

1 reference

27 May 2018

author name string

Xiu Luo

1

1 reference

27 May 2018

Linlin Pan

2

1 reference

27 May 2018

Aifang Nie

3

1 reference

27 May 2018

Qidi Wang

4

1 reference

27 May 2018

Yanyun Gu

5

1 reference

27 May 2018

Fengying Li

6

1 reference

27 May 2018

Hongli Zhang

7

1 reference

27 May 2018

Wenyi Li

8

1 reference

27 May 2018

Xiaoying Li

9

1 reference

27 May 2018

publication date

4 June 2013

1 reference

27 May 2018

published in

Journal of diabetes

1 reference

27 May 2018

volume

5

1 reference

27 May 2018

issue

4

1 reference

27 May 2018

page(s)

421-428

1 reference

27 May 2018

Fate of the beta-cell in the pathophysiology of type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

beta-Cell death during progression to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

IL-1β activation as a response to metabolic disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Increased number of islet-associated macrophages in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective po

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Thioredoxin-interacting protein links oxidative stress to inflammasome activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

Islet structure and function in the GK rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12061

21 January 2018

Identifiers

DOI

10.1111/1753-0407.12061

1 reference

27 May 2018

PubMed ID

23590680

1 reference

27 May 2018